ApoB: what your result means.

Apolipoprotein B (ApoB) is a direct count of every cholesterol particle capable of entering your artery wall and forming plaque. One ApoB protein sits on each LDL, VLDL, IDL and Lp(a) particle. That makes it a particle count, not a cholesterol weight, and a growing body of evidence shows it predicts cardiovascular risk better than standard LDL cholesterol.

Why ApoB matters

Two people with identical LDL-C can carry very different numbers of atherogenic particles. When LDL-C and ApoB disagree, the evidence shows ApoB better predicts heart attacks and strokes, which is why European guidelines position it as a primary risk marker, especially with high triglycerides, diabetes, obesity or metabolic syndrome.

Associated risks when out of range: Atherosclerosis. Cardiovascular disease. Plaque progression.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets ApoB, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• INTERHEART study (Yusuf et al. The Lancet 2004): across 52 countries and ~30,000 participants, the ApoB/ApoA1 ratio was the strongest single modifiable risk factor for heart attack, explaining roughly half of population-attributable risk, ahead of smoking, hypertension and diabetes.
• Mendelian randomisation analysis (Ference et al. JAMA 2019): genetic variants that lower cardiovascular risk do so in proportion to the reduction in ApoB particle count, not cholesterol mass, supporting ApoB as the fundamental causal unit of atherogenic risk.
• Discordance analysis (Marston et al. JAMA Cardiology 2022): in ~390,000 UK Biobank participants, ApoB was the primary driver of myocardial infarction risk; once ApoB was accounted for, LDL-C and triglycerides added no meaningful predictive information.
• Narrative review of the particle paradigm (Sniderman et al. JAMA Cardiology 2019): synthesising decades of evidence that ApoB particle number outperforms LDL-C, particularly in the common discordant patients, those with metabolic syndrome, diabetes or high triglycerides.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets ApoB against published clinical authority standards, never arbitrary "optimal" ranges. Measured in g/L:

Band	Range (g/L)
Optimal	<0.80 g/L
Borderline	0.80–1.00 g/L
High	1.01–1.30 g/L
Very high	>1.30 g/L

Clinical interpretation

• ApoB counts all atherogenic particles (LDL, VLDL, IDL, Lp(a)), superior to LDL-C for risk stratification.
• Discordance between LDL-C and ApoB is common; when they disagree, ApoB better predicts events.
• One ApoB molecule per atherogenic particle. It is a direct particle count.
• ESC/EAS emphasises ApoB as primary or alternative risk marker in people with high triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL-C.

What improves it: the evidence-based levers

• Reduce saturated fat
• Increase soluble fibre
• Exercise
• Weight reduction
• Discuss medication if persistent

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How ApoB testing works at HodieLabs

ApoB is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004;364:937–952.
2. Ference BA, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364–373.
3. Marston NA, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis. JAMA Cardiol. 2022;7:250–256.
4. Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287–1295.
5. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41:111–188.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.